亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Novel Matrix Metalloproteinase Inhibitors

详细技术说明: Matrix Metalloproteinases (MMPs) are zinc containing hydrolytic enzymes that are able to degrade extracellular matrix components such as collagen. MMP’s have been implicated in a variety of diseases, including cancer, arthritis, inflammatory disease, and heart disease. Despite intensive research and clinical testing of MMP inhibitors, the only approved MMP inhibitor is a tetracycline for the treatment of periodontitis. UCSD researchers have developed a novel series of organic compounds that are potent inhibitors of MMPs. While most MMP inhibitors in development are based on small peptide mimetics that chelate the zinc ion using a hydroxamic acid moiety, the UCSD researchers designed a novel class of zinc-binding groups (ZBGs) by rational drug design. The binding mode of the ZBGs was optimized using structural, spectroscopic, and computational studies of the compounds bound to an inorganic zinc model complex for MMP’s. These new inhibitors are up to 700-fold more potent than acetohydroxamic acid in MMP binding assays and are expected to have better oral availability and pharmacokinetics when compared with hydroxamate-based compounds. These ZBG inhibitors have commercial applications in drug design against MMP’s and other metalloproteins related to human disease, such as histone deacetylases.

*Principal Investigation: Name: Seth Cohen
Department:

Name: Jana Lewis
Department:

Name: David Puerta
Department:

附加资料: Patent Number: US7705164B2
Application Number: US2006568505A
Inventor: Puerta, David T. | Cohen, Seth M. | Lewis, Jana A.
Priority Date: 29 Apr 2004
Priority Number: US7705164B2
Application Date: 22 Aug 2007
Publication Date: 27 Apr 2010
IPC Current: C07D031500 | A61K0031167 | A61K003135 | A61K0031435 | C07D021362 | C07D021369 | C07D030936 | C07D030938 | C07D030940
US Class: 549420 | 546261 | 549418
Assignee Applicant: The Regents of the University of California
Title: Metalloprotein inhibitors
Usefulness: Metalloprotein inhibitors
Summary: In pharmaceutical compositions for treating pathology associated with metalloprotein activity e.g. elevated metalloprotein activity, including cancer, inflammation, myocardial infarction (claimed), anthrax pathogenesis, arthritis, rheumatoid arthritis, restenosis, aortic aneurism, irritable bowel disease, glomerular nephritis, multiple sclerosis, stroke, diabetes, bacterial meningitis, graft versus host disease, Hodgkin's lymphoma, osteosarcoma, germ cell tumor, lung cancer, myelodysplastic syndrome, Ewing's sarcoma, Paget's disease, epidermal scars and periodontal disease.
Novelty: New hydroxypyridinone, hydroxypyridinethione, pyrone and thiopyrone compounds useful as metalloprotein inhibitors for treating e.g. cancer and inflammation

其他

Additional Technologies by these Inventors

Tech ID/UC Case

19604/2004-102-0

Related Cases

2004-102-0

欲了解更多信息，请点击这里